Australia's most trusted
source of pharma news
Thursday, 03 April 2025
Posted 2 April 2025 AM
The Aussie CEO of Lexicon, Mike Exton, has signed another deal, this one securing up to $1.6 billion from Novo Nordisk for a novel obesity drug.
Novo signed a world-wide licensing deal for LX9851, a first-in-class, oral non-incretin pre-clinical drug for which Lexicon plans to submit an Investigational New Drug (IND) application this year. It gives Novo another arrow in its quiver for capturing the booming obesity market.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.